Acadia's newly approved Parkison's disease drug could trigger a buyout. Here's why.
A collection of underperforming stocks held by Soros Fund Management that could be set to bounce strongly.
Achillion Pharmaceuticals, Ophthotech Corp., and Kite Pharmaceuticals shares could move wildly because of upcoming trial data.
Billionaire money managers reduced their holdings in these popular stocks last quarter, but was it a smart move?
Offhand comments from Abbott's CEO, and a confusing statement from Alere makes a pending acquisition doubtful.
The biotech's numbers are meaningless, but an update on one of its programs sent the stock down.
Less-than-convincing comments from acquirer Abbott Labs are causing a sell-off.
Our healthcare contributors think these five stocks might be on big pharma's shopping list.
It was a good week for healthcare ETFs, but this one fund put up a stellar performance.
The stock market was lucky to get back to breakeven, but these stocks soared. Find out why.